LRIG3 Antibody AF3495 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemLRIG3 Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price $479.00Supplier Page View Company Product Page
Catalog NumberAF3495
NCBI Gene AliasesLIG3
ApplicationsImmunohistochemistry,Western Blot
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
TargetLRIG3
Conjugate/TagUnconjugated
ReactivityHuman
HostGoat
Quantity100 ug (also 25 ug)
IsotypeIgG
NCBI Full Gene Nameleucine rich repeats and immunoglobulin like domains 3
ClonalityPolyclonal
ImmunogenMouse myeloma cell line NS0-derived recombinant human LRIG3 isoform 1 (R&D Systems, Catalog # 3495-LR), Asp28-Thr807, Accession # Q6UXM1
ConcentrationLYOPH
PurityAntigen Affinity-purified
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution

Specifications/Features

Available conjugates: Available conjugates: Unconjugated

Specificity: Detects human LRIG3 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant mouse LRIG1 is observed.

Sizes Available: 100 ug (also 25 ug)

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) LRIG3 Suppresses Angiogenesis by Regulating the PI3K/AKT/VEGFA Signaling Pathway in GliomaFrontiers in oncologyJanuary 1, 2021Peng C, Chen H, Li Y, Yang H, Qin P, Ma B, Duan Q, Wang B, Mao F, Guo D.quantified using the densitometric analysis software (ImageJ, USA). Primary antibodies against LRIG3 (Cat #AF3495, R&D Systems), AKT (Cat #2920, Cell Signaling Technology), p-AKT (Ser473) (Cat #4060, Cell Signaling Technology

(2) The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in GlioblastomaFrontiers in oncologyJanuary 1, 2019Cheng F, Zhang P, Xiao Q, Li Y, Dong M, Wang H, Kuang D, He Y, Duan Q, Mao F, et al.primary antibodies were used: mouse anti-FLAG (Sigma, Cat# F1804), goat anti-LRIG3 (R&D Systems, Cat# AF3495, recognizes the ectodomain of LRIG3 protein, Arg28-Thr807), rabbit anti-EGFR (Abcam, Cat# ab131498),

(3) Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3)The Journal of biological chemistryJuly 26, 2013Rafidi H, Mercado F 3rd, Astudillo M, Fry WH, Saldana M, Carraway KL 3rd, Sweeney C.

Be the First to Write a Review!

LRIG3 Antibody

LRIG3 Antibody

LRIG3 Antibody

LRIG3 Antibody from R&D Systems, a Bio-Techne Brand

Specifications/Features

R&D Systems, a Bio-Techne Brand

Citations (3)

Reviews

LRIG3 Antibody from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map